The α2-adrenoceptor antagonist atipamezole potentiates anti-Parkinsonian effects and can reduce the adverse cardiovascular effects of dopaminergic drugs in rats

@article{Haapalinna2003TheA,
  title={The $\alpha$2-adrenoceptor antagonist atipamezole potentiates anti-Parkinsonian effects and can reduce the adverse cardiovascular effects of dopaminergic drugs in rats},
  author={A. Haapalinna and T. Leino and E. Heinonen},
  journal={Naunyn-Schmiedeberg's Archives of Pharmacology},
  year={2003},
  volume={368},
  pages={342-351}
}
The present experiments investigated the effects of the specific α2-adrenoceptor antagonist atipamezole, alone and in combination with a dopamine agonist, on motor function in rats with a unilateral 6-hydroxydopamine lesion of the nigro-striatal pathway and on exploratory behaviour and cardiovascular function in rats equipped with telemetry transmitters. Dexmedetomidine, an α2-adrenoceptor agonist and the α2-adrenoceptor antagonists idazoxan and yohimbine were used as reference compounds. In… Expand
The effect of the α2-adrenoreceptor antagonist idazoxan against 6-hydroxydopamine-induced Parkinsonism in rats: multiple facets of action?
TLDR
It is indicated that systemic administration of idazoxan counteracts 6-OHDA-induced Parkinsonian symptoms in rats and that both dopaminergic and serotonergic mechanisms could contribute to its anti-Parkinsonian effect. Expand
Serotonergic influence on the potentiation of D-amphetamine and apomorphine-induced rotational behavior by the α2-adrenoceptor antagonist 2-methoxy idazoxan in hemiparkinsonian rats
TLDR
It is indicated that an increase in noradrenergic tone by 2-methoxy idazoxan potentiates both D-amphetamine-induced ipsilateral and apomorphine induced contralateral rotations, whereas increases and decreases apomorphicine potentiation respectively. Expand
Treatment with α2-adrenoceptor antagonist, 2-methoxy idazoxan, protects 6-hydroxydopamine-induced Parkinsonian symptoms in rats: neurochemical and behavioral evidence
TLDR
Testing whether treatment with the selective alpha2-adrenoceptor antagonist, 2-methoxy idazoxan, before an experimental lesion to nigra, protects dopaminergic neurodegeneration in Parkinson's disease indicates neuroprotection. Expand
Anticataleptic properties of α2 adrenergic antagonists in the crossed leg position and bar tests: differential mediation by 5-HT1A receptor activation
TLDR
Serotonin 5-HT1A receptors play a prominent role in anticataleptic effects of certain α2 adrenergic antagonists in the CLP test, whereas α2-adrenergic mechanisms are likely to be primarily responsible for the anticatalesptic effects of these ligands in the bar test. Expand
Effects of noradrenergic denervation on L-DOPA-induced dyskinesia and its treatment by α- and β-adrenergic receptor antagonists in hemiparkinsonian rats
TLDR
It is demonstrated that moderate NE loss reduced the development and expression of AIMs and rotations but not L-DOPA efficacy while anti-dyskinetic efficacy of α2- and β-adrenergic receptor blockade was maintained. Expand
Pharmacological profile of intrathecal fadolmidine, a α2-adrenoceptor agonist, in rodent models
TLDR
Investigation of the peripheral and central pharmacological effects of three α2-adrenoceptor agonists after single intrathecal bolus injections in rats supports that intrathecally administered fadolmidine could have potential to be used as an analgesic agent with less subraspinal or spinal adverse effects at analgesic doses than dexmedetomidine and clonidine. Expand
Pharmacological properties, central nervous system effects, and potential therapeutic applications of atipamezole, a selective alpha2-adrenoceptor antagonist.
TLDR
Recent experimental animal studies suggest that atipamezole might have beneficial effects in the recovery from brain damage and might potentiate the anti-Parkinsonian effects of dopaminergic drugs. Expand
Modulation of l-DOPA's antiparkinsonian and dyskinetic effects by α2-noradrenergic receptors within the locus coeruleus
TLDR
Results demonstrate that α2R play an important modulatory role in l-DOPA-mediated behaviors and should be further investigated as a potential therapeutic target. Expand
The involvement of noradrenergic mechanisms in the suppressive effects of diazepam on the hypothalamic-pituitary-adrenal axis activity in female rats
TLDR
The results suggest that α2-adrenoreceptors activity, as well as intact presynaptic noradrenergic function, are required for the suppressive effect of diazepam on the HPA axis activity. Expand
Modulation of the motor response to dopaminergic drugs in a parkinsonian model of combined dopaminergic and noradrenergic degeneration.
TLDR
It is suggested that additional noradrenergic denervation selectively decreases the motor threshold to l-DOPA treatment without modifying the magnitude or the pattern of the motor response to adenosinergic antagonism. Expand
...
1
2
3
4
...

References

SHOWING 1-10 OF 57 REFERENCES
Effects of alpha-2 adrenoceptor agonists and antagonists on circling behavior in rats with unilateral 6-hydroxydopamine lesions of the nigrostriatal pathway.
TLDR
The effects on apomorphine-induced circling indicate an influence of alpha-2 adrenoceptor compounds on nigrostriatal neurotransmission at sites downstream from the dopaminergic neurons themselves. Expand
The α2-adrenoceptor antagonist atipamezole reduces the development and expression of d-amphetamine-induced behavioural sensitization
TLDR
Results indicate that α2-adrenoceptor antagonists modulate the actions of d-amphetamine in a manner not explicable by their enhancing actions on noradrenaline and dopamine release, and may thus provide a novel approach to the treatment of motor complications caused by dopaminergic agents, such as dyskinesias, and perhaps also drug dependence. Expand
Evaluation of the effects of a specific α2-adrenoceptor antagonist, atipamezole, on α1- and α2-adrenoceptor subtype binding, brain neurochemistry and behaviour in comparison with yohimbine
In the present study we evaluated the α1- and α2-adrenoceptor subtype binding, central α2-adrenoceptor antagonist potency, as well as effects on brain neurochemistry and behavioural pharmacology ofExpand
Effects of α2-adrenoceptor agonists on locus coeruleus firing rate and brain noradrenaline turnover in N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline (EEDQ)-treated rats
TLDR
The data support the notion that EEDQ decreases the responsiveness of brain α2-adrenergic receptors and indicate that α2 -adrenoceptors regulating LC activity are characterized by a larger receptor reserve or are less sensitive to the influence of alkylation than are the population of α2 toceptor agonists regulating noradrenaline utilization. Expand
Specific α2-adrenoreceptor antagonists induce behavioural activation in the rat
The behavioural effects of the specific and selective α2-adrenoreceptor antagonists, idazoxan, efaroxan and RX811059, have been investigated in the rat. All three drugs induced periods of behaviouralExpand
Differential modulation of (+)-amphetamine-induced rotation in unilateral substantia nigra-lesioned rats byα1 as compared toα2 agonists and antagonists
Abstract In rats sustaining unilateral 6-hydroxy-dopamine lesions of the substantia nigra (SN), the indirect dopaminergic agonist, (+)-amphetamine (AMPH), dose-dependently induced robust, ipsilateralExpand
The alpha 2-adrenoceptor antagonist idazoxan is an agonist at 5-HT1A autoreceptors modulating serotonin synthesis in the rat brain in vivo.
TLDR
The results indicate that idazoxan is a potent and specific agonist at 5-HT1A autoreceptors modulating brain serotonin synthesis in vivo. Expand
Actions of α2 adrenoceptor ligands at α2A and 5-HT1A receptors: the antagonist, atipamezole, and the agonist, dexmedetomidine, are highly selective for α2A adrenoceptors
This study examined the activity of chemically diverse α2 adrenoceptor ligands at recombinant human (h) and native rat (r) α2A adrenoceptors as compared with 5-HT1A receptors. First, in competitionExpand
Alpha2-adrenergic control of dopamine overflow and metabolism in mouse striatum.
TLDR
It is suggested that alpha2-adrenoceptors in dopaminergic terminal fields in the mouse striatum are involved in the regulation of dopamine release at physiological stimulation frequencies. Expand
Central alpha 2-adrenoceptors are highly stereoselective for dexmedetomidine, the dextro enantiomer of medetomidine.
TLDR
These experiments demonstrate that the different alpha 2-adrenoceptor-mediated functions have similar stereochemical requirements in the central nervous system. Expand
...
1
2
3
4
5
...